InMed Pharmaceuticals Inc.

For the period ended Jun 30, 2025. Filed Sep 23, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Sep 23, 2025

INM$15.56+17.8%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Shareholders’ Equity

For the years ended June 30, 2025 and 2024

Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total
	#	$	$	$	$	$
Balance July 1, 2024	445,908	82,784,400	35,368,899	(109,075,759)	128,569	9,206,109
Proceeds from ATM (Note 8)	313,242	1,905,583	-	-	-	1,905,583
Proceeds from SEPA (Note 8)	1,208,336	6,224,716	-	-	-	6,224,716
Proceeds from Private Placement	-	-	5,024,891	-	-	5,024,891
Share issuance costs	-	(269,559)	(614,419)	-	-	(883,978)
Exercise of pre-funded warrants	34,700	576,034	(576,034)	-	-	-
Loss for the period	-	-	-	(8,162,133)	-	(8,162,133)
Share-based compensation	-	-	119,307	-	-	119,307
Balance June 30, 2025	2,002,186	91,221,174	39,322,644	(117,237,892)	128,569	13,434,495

Common Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income · Total
	#	$	$	$	$	$
Balance July 1, 2023	166,370	77,620,252	35,741,115	(101,400,209)	128,569	12,089,727
Proceeds from Private Placement	163,637	3,240,006	1,976,187	-	-	5,216,193
Share issuance costs	-	-	(562,151)	-	-	(562,151)
Exercise of pre-funded warrants	115,901	1,924,142	(1,923,967)	-	-	175
Loss for the period	-	-	-	(7,675,550)	-	(7,675,550)
Share-based compensation	-	-	137,715	-	-	137,715
Balance June 30, 2024	445,908	82,784,400	35,368,899	(109,075,759)	128,569	9,206,109

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.